2068-78-2

• 常用中文名：硫酸长春新碱
• 常用英文名：Vincristine Sulfate
• CAS号：2068-78-2
• 分子式：C₄₆H₅₈N₄O₁₄S
• 分子量：923.036
• 相关类别： 原料药 抗肿瘤药 天然来源类抗肿瘤药
• 发布时间：2018-06-15 12:40:55
• 更新时间：2026-07-01 01:24:08
• Vincristine sulfate是一种抗肿瘤长春花生物碱,抑制有丝分裂纺锤体中的 microtubule 形成,导致中期阶段的分裂细胞停滞。 它与 microtubule 结合的 Ki 为85 nM。

名称

• 中文名: 硫酸长春新碱
• 英文名: Vincristine Sulfate
• 中文别名: 长春新碱 硫酸盐, 来源于长春花; 长春新碱 硫酸盐; 硫酸长春新碱 Vincristine Sulfate; 硫酸长春新碱对照品; 长春瑞滨杂质4; 硫酸盐长春新碱; 长春新碱硫酸盐; 新长春碱; 硫酸长春新碱 (长春新碱硫酸盐); 硫酸长春新碱(硫酸长春醛碱); 长春醛碱 硫酸盐; 硫酸长春新碱/硫酸醛基长春碱(标准品); 长春新碱 磺酸盐; 硫酸醛基长春碱,硫酸长春醛碱; Vincristine sulfate 10mM * 1mL in DMSO试剂; 醛基长春碱; 硫酸长春新碱 标准品; (3,3A1R,4R,5S,5,10BR)-甲基 4-乙酰氧基-3A-乙基-9-((3S,5S,7S,9S)-5-乙基-5-羟基-9-(甲氧基羰基)- 2,4,5,6,7,8,9,10-八氢-1H-3,7-甲基氮杂环十一烷并[5,4-B]吲哚-9-基)-6-甲酰基-5-羟基-8-甲氧基-3A,3A1,4,5,5A,6,11,12-八氢-1H-INDOLIZINO [8,1-CD]咔唑-5-羧酸酯硫酸盐; 长春新碱硫化物; 硫酸长春新碱/D1A; 替莫唑胺; 长春新碱 硫酸酯; 硫酸长春新碱/生物碱类; VINCRISTINE SULFATE 硫酸长春新碱; 硫酸长春新碱,10 MM DMSO 溶液; 硫酸长春新碱标准品; 醛基长春碱 硫酸盐; 硫酸长春新碱/硫酸醛基长春碱; 硫酸醛基长春碱,醛基长春碱、硫酸长春醛碱、新长春碱; 硫酸醛基长春碱; LEUROCRISTINE|||22-OXOVINCALEUKOBLASTINE SULFATE|||LEUROCRISTINE SULFATE|||硫酸长春新碱; VINCRISTINE SULFATE SALT,MICROTUBULE抑制剂; 硫酸长春醛碱
• 英文别名: oncovin; Vincristin Sulfate; Methyl-(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-form; Vincristine sulfate salt,22-Oxovincaleukoblastine sulfate salt, Leurocristine sulfate salt, VCR; V5 PEPTIDE; VCR, LEUKOCRISTINE SULFATE; VINCRISTINE SULFATE, WHO STANDD; (2'β)-22-Oxovincaleukoblastine sulfate (1:1); Vincristine sulfate salt; onkovin; VINCRISTINE SULPHATE; Vincaleukoblastine, 22-oxo-, sulfate (1:1) (salt); Vincristine Sulfate, Apocynaceae sp; MFCD00084729; LEUROCRISTINE SULFATE; Vincristine sulphate 25; yl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate (salt); vincristin; methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-form; VCR SULFATE; VINCRISTINE SULFATE, STANDD; (3aR,4R,5S,5aR,10bR,13aR)-4-(acétyloxy)-3a-éthyl-9-[(13S,15S,17S)-17-éthyl-17-hydroxy-13-(méthoxycarbonyl)-1,11-diazatétracyclo[13.3.1.0.0]nonadéca-4(12),5,7,9-tétraén-13-yl]-6-formyl-5-hy; LEUROCRISTINE; Vincristine Sulfate, Apocynaceae sp. - - Calbiochem; leurocristinesulfate(1:1)(salt); vincristinsulfat; Vincristine sulfate from Vinca rosea L; vincaleukoblastine, 22-oxo-, (3β,4'β)-, sulfate (1:1); VINCRISTINE SULFATE, APOCYNACEAE SPECIES; Vinorelbine Impurity 4; 22-Oxovincaleukoblastine sulfate salt,Leurocristine sulfate salt,VCR; LEUROCRISTINE SULFATE SALT; droxy-8-méthoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate de méthyle sulfate (salt); VINCRISTINE SULFATE, REFERENCE SPECTRUM STANDD; Vincristine，Leurocristine，Oncovin，Vinblastine; V5 PTIDE; NSC-67574 sulfate; lilly37231; (3aR,4R,5S,5aR,10bR,13aR)-4-(acétyloxy)-3a-éthyl-9-[(13S,15S,17S)-17-éthyl-17-hydroxy-13-(méthoxycarbonyl)-1,11-diazatétracyclo[13.3.1.0.0]nonadéca-4(12),5,7,9-tétraén-13-yl]-6-formyl-5-hydroxy-8-méthoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate de méthyle sulfate (salt); Vincristine Sulfate (50 mg); VCR, LCR, Kyocristine, Oncovin, Vincrex; leurocristinesulfate(1:1); Vinorelbine Impurity; nsc67574; Vincristine Sufate; VCR; Vincristine Sulfate (Assay) (29.8 mg/vial); Vincrisul; 22-Oxovinacleukoblastine sulfate; (2'b)-22-oxovincaleukoblastine sulfate (1:1); NovopharM; 22-OXOVINCALEUKO-BLASTINE SULFATE; kyocristine; Vincristine Sulfate (50 mg/ampule); 22-Oxovincaleukoblastine Sulfate (1:1) (salt); 22-Oxovinacleukoblastine; 22-oxovincaleukoblastine sulfate; Vincaleukoblastine, 22-oxo-, sulfate (1:1); methyl (3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-formyl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate (salt); vincaleukoblastine, 22-oxo-, (2'b)-, sulfate (1:1); LEUROCRISTINESULPHATE; Vincristine sulfate; yl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-5-carboxylatsulfat(salt); vinorelbine，NVB; Vincaleukoblastine, 22-oxo-, (2'β)-, sulfate (1:1); 22-OXOVINCALEUKOBLASTINE; Methyl-(3aR,4R,5S,5aR,10bR,13aR)-4-(acetyloxy)-3a-ethyl-9-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0.0]nonadeca-4(12),5,7,9-tetraen-13-yl]-6-formyl-5-hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-5-carboxylatsulfat(salt); EINECS 218-190-0; (3,3a1R,4R,5S,5,10bR); 22-oxo-vincaleukoblastinsulfate(1:1)(salt); Vincristine (sulfate); Vincristine; VINCRISTINE SULFATE SALT; VincristineSulphate28/Bp2003; 22-OXOVINCALEUKOBLASTINE SULFATE SALT; VINCRISTINE SULFATE; Vincristine sulfate from Cathanthus roseus (L.) G. Don; NovophM; VINCRISTINE, VCR

物化性质

• 沸点: 273-281 °C
• 熔点: 300 °C
• 分子式: C₄₆H₅₈N₄O₁₄S
• 分子量: 923.036
• 精确质量: 922.367004
• PSA: 254.15000
• LogP: 4.52220
• 外观性状: 白色结晶粉末
• 储存条件:

  充氩气密封于4℃干燥避光保存。

• 水溶解性: >=1 G/100 ML AT 24 ºC
• 计算化学:

  1、 疏水参数计算参考值（XlogP）：

  2、 氢键供体数量：5

  3、 氢键受体数量：16

  4、 可旋转化学键数量：10

  5、 互变异构体数量：

  6、 拓扑分子极性表面积（TPSA）：246

  7、 重原子数量：65

  8、 表面电荷：0

  9、 复杂度：1830

  10、同位素原子数量：0

  11、确定原子立构中心数量：9

  12、不确定原子立构中心数量：0

  13、确定化学键立构中心数量：0

  14、不确定化学键立构中心数量：0

  15、共价键单元数量：2

• 更多:

  1. 性状：晶体状粉末，有恶臭气味。

  2. 密度（g/mL,25/4℃）： 未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：300 ºC

  5. 沸点（ºC,常压）：273-281 ºC

  6. 沸点（ºC,13mmHg）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：未确定

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25ºC）：：未确定

  12. 饱和蒸气压（kPa,60ºC）：：未确定

  13. 燃烧热（KJ/mol）：：未确定

  14. 临界温度（ºC）：：未确定

  15. 临界压力（KPa）：：未确定

  16. 油水（辛醇/水）分配系数的对数值：：未确定

  17. 爆炸上限（%,V/V）：：未确定

  18. 爆炸下限（%,V/V）：：未确定

  溶解性： >=1 g/100 mL at 24 ºC ：。

生物活性

• 描述: Vincristine sulfate是一种抗肿瘤长春花生物碱,抑制有丝分裂纺锤体中的 microtubule 形成,导致中期阶段的分裂细胞停滞。 它与 microtubule 结合的 Ki 为85 nM。
• 相关类别:
  信号通路 >> 细胞周期/DNA损伤 >> 微管/微管蛋白
  信号通路 >> 细胞骨架 >> 微管/微管蛋白
  天然产物 >> 生物碱
  研究领域 >> 癌症
• 体外研究: 长春新碱抑制稳态微管组装末端微管蛋白二聚体的净添加,Ki为85 nM [1]。长春新碱稳定心轴装置,导致染色体不能分离,导致中期停滞和低浓度的有丝分裂抑制。在较高浓度下,长春新碱可能会破坏并诱导微管的完全解聚[2]。长春新碱诱导肿瘤细胞凋亡,抑制SH-SY5Y细胞增殖,IC50为0.1μM。长春新碱诱导有丝分裂停滞并促进caspase-3和-9和cyclin B的表达,同时降低cyclin D的表达[3]。长春新碱诱导的神经毒性是由于干扰微管功能引起的,导致轴突运输受阻,从而导致轴突变性[4]。
• 体内研究: 长春新碱(3mg/kg,ip)诱导平均生长延迟> 120和> 52天,并且重新填充0.06％和5％的组分,分别在携带双侧皮下异种移植物Rh12或Rh18的小鼠中给药[5]。
• 细胞实验: 将细胞以约5×10 4个细胞/ mL的浓度接种在35mm板中的2mL培养基中，并在37℃，5％CO 2和95％空气的气氛中生长24小时。然后用缺乏或含有4nM药物的新鲜培养基替换培养基，并继续增殖3天。在用胰蛋白酶和EDTA分离细胞后，每天在库尔特计数器中进行细胞计数。
• 参考文献:

  [1]. Jordan, M.A., et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 1985. 45(6): p. 2741-7.

  [2]. Gidding, C.E., et al, Vincristine revisited. Crit Rev Oncol Hematol, 1999. 29(3): p. 267-87.

  [3]. Donoso, J.A., et al, Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro. Cancer Res, 1977. 37(5): p. 1401-7.

  [4]. Horton, J.K., et al. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts. Biochem Pharmacol, 1988. 37(20): p. 3995-4000.

  [5]. Baguley, B.C., et al, Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 1991. 27(4): p. 482-7.

  [6]. Zhang D, et al. Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. Int J Nanomedicine. 2017 Mar 16;12:2081-2108.

MSDS

Name: Vincristine sulfate 95% (hplc) Material Safety Data Sheet Synonym: Leurocristine sulfate (1:1 CAS: 2068-78-2 Section 1 - Chemical Product MSDS Name:Vincristine sulfate 95% (hplc) Material Safety Data Sheet Synonym:Leurocristine sulfate (1:1 Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS CAS# Chemical Name content EINECS# 2068-78-2 Vincristine sulfate 95 218-190-0 Hazard Symbols: T Risk Phrases: 23/24/25 Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Toxic by inhalation, in contact with skin and if swallowed.Hygroscopic (absorbs moisture from the air).Light sensitive. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. May be harmful if absorbed through the skin. Ingestion: May cause irritation of the digestive tract. May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May cause liver and kidney damage. May cause bone marrow depression. Inhalation: May cause respiratory tract irritation. May cause effects similar to those described for ingestion. Chronic: Chronic exposure may cause reproductive disorders and teratogenic effects. Section 4 - FIRST AID MEASURES Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Skin: Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Ingestion: Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Inhalation: Get medical aid immediately. Remove from exposure and move to fresh air immediately. Do not use mouth-to-mouth resuscitation if victim ingested or inhaled the substance; induce artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper respiratory medical device. Notes to Physician: Treat symptomatically and supportively. Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing Media: Use carbon dioxide, dry chemical powder or water spray. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Wash area with soap and water. Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation. Section 7 - HANDLING and STORAGE Handling: Wash thoroughly after handling. Use with adequate ventilation. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Store protected from light. Use only in a chemical fume hood. Do not breathe dust or fumes. Storage: Store in a tightly closed container. Keep refrigerated. (Store below 4C/39F.) Store protected from moisture. Store protected from light. Store in a cool, dry area away from incompatible substances. Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 2068-78-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Powder Color: white to pale yellow Odor: none reported pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: > 300 deg C Autoignition Temperature: Not applicable. Flash Point: Not applicable. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Not available. Solubility in water: soluble Specific Gravity/Density: Not available. Molecular Formula: C46H58N4O14S Molecular Weight: 923.03 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable under normal temperatures and pressures. Light sensitive. Conditions to Avoid: Incompatible materials, excess heat, exposure to moist air or water, excess light. Incompatibilities with Other Materials: Strong oxidizing agents, heat, moisture, heavy metal salts, direct light. Hazardous Decomposition Products: Carbon monoxide, oxides of nitrogen, oxides of sulfur, irritating and toxic fumes and gases, carbon dioxide. Hazardous Polymerization: Will not occur. Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 2068-78-2: OH6340000 LD50/LC50: Not available. Carcinogenicity: Vincristine sulfate - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Other No information available. Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.* Hazard Class: 6.1 UN Number: 2811 Packing Group: II IMO Shipping Name: TOXIC SOLID, ORGANIC, N.O.S. Hazard Class: 6.1 UN Number: 2811 Packing Group: II RID/ADR Shipping Name: TOXIC SOLID, ORGANIC, N.O.S. Hazard Class: 6.1 UN Number: 2811 Packing group: II Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: T Risk Phrases: R 23/24/25 Toxic by inhalation, in contact with skin and if swallowed. Safety Phrases: S 24/25 Avoid contact with skin and eyes. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 2068-78-2: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 2068-78-2 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 2068-78-2 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : OH6340000 CAS REGISTRY NUMBER : 2068-78-2 LAST UPDATED : 199801 DATA ITEMS CITED : 49 MOLECULAR FORMULA : C46-H56-N4-O10.H2-O4-S MOLECULAR WEIGHT : 923.14 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1900 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1010 ug/kg TOXIC EFFECTS : Gastrointestinal - hypermotility, diarrhea Kidney, Ureter, Bladder - urine volume increased Blood - normocytic anemia TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 3 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1700 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Primate - monkey DOSE/DURATION : >4 mg/kg TOXIC EFFECTS : Behavioral - food intake (animal) Gastrointestinal - hypermotility, diarrhea Blood - changes in bone marrow (not otherwise specified) TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Primate - monkey DOSE/DURATION : 4 mg/kg TOXIC EFFECTS : Behavioral - food intake (animal) Gastrointestinal - hypermotility, diarrhea Blood - changes in bone marrow (not otherwise specified) TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Bird - chicken DOSE/DURATION : 4 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 4500 ug/kg/21D-I TOXIC EFFECTS : Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1500 ug/kg/3D-I TOXIC EFFECTS : Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1250 ug/kg/33D-I TOXIC EFFECTS : Endocrine - other changes Blood - changes in bone marrow (not otherwise specified) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4 mg/kg/4D-I TOXIC EFFECTS : Gastrointestinal - alteration in gastric secretion Endocrine - other changes Related to Chronic Data - death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - cat DOSE/DURATION : 1450 ug/kg/16W-I TOXIC EFFECTS : Peripheral Nerve and Sensation - recording from afferent nerve Peripheral Nerve and Sensation - recording from peripheral motor nerve TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 600 ug/kg SEX/DURATION : male 15 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Paternal Effects - other effects on male TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 1250 ug/kg SEX/DURATION : male 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 250 ug/kg SEX/DURATION : female 8 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 300 ug/kg SEX/DURATION : female 7 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 250 ug/kg SEX/DURATION : female 9 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 250 ug/kg SEX/DURATION : female 9 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 250 ug/kg SEX/DURATION : female 9 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 250 ug/kg SEX/DURATION : female 9 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 750 ug/kg SEX/DURATION : female 9 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : Sperm Morphology TYPE OF TEST : Micronucleus test TYPE OF TEST : Micronucleus test TYPE OF TEST : Micronucleus test TYPE OF TEST : Micronucleus test TYPE OF TEST : Sex chromosome loss and nondisjunction TYPE OF TEST : Dominant lethal test TYPE OF TEST : Micronucleus test TYPE OF TEST : Sex chromosome loss and nondisjunction MUTATION DATA TYPE OF TEST : Sex chromosome loss and nondisjunction TEST SYSTEM : Rodent - hamster Ovary DOSE/DURATION : 125 ug/L REFERENCE : MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 379,83,1997 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,365,1981 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,365,1981 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,372,1987 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M2867 No. of Facilities: 33 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 1452 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M2867 No. of Facilities: 476 (estimated) No. of Industries: 1 No. of Occupations: 8 No. of Employees: 18880 (estimated) No. of Female Employees: 13761 (estimated)

安全

• 符号: GHS06, GHS08
• 信号词: Danger
• 危害声明: H300-H341-H361fd
• 警示性声明: Missing Phrase - N15.00950417-P280
• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危害码 (欧洲): T:Toxic
• 风险声明 (欧洲): R36/37/38;R61
• 安全声明 (欧洲): 22-24/25-53-45-37/39-26-36/37/39
• 危险品运输编码: UN 2811 6.1/PG 2
• WGK德国: 3
• RTECS号: OH6340000
• 包装等级: II
• 危险类别: 6.1(a)
• 海关编码: 2942000000

上下游产品

上游产品  0
下游产品  1
57-22-7

海关

海关编码	2942000000